연구성과로 돌아가기
2024 연구자 정보 (44 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Chuken, Yamil Alonso Lopez (Chuken, YAL) |
I Can Oncol Ctr, New Leon, Mexico |
|
|
[JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | bsangro@unav.es; | ||
|
Chung, Ik Joo (Chung, IJ) |
Chonnam Natl Univ, Chonnam Natl Univ Hwasun Hosp, Dept Internal Med, Med Sch, Jeonnam, South Korea |
|
0000-0003-0479-8067 Chung, Ik-Joo |
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Chung, Liam Il Young (Chung, LIY) |
IQU-0821-2023 Chung, Liam Il-Young |
|
[JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. [JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY | ||||
|
Chung, Liam Il-Young (Chung, LIY) |
Northwestern Univ, Feinberg Sch Med, Chicago, IL USA |
IQU-0821-2023 Chung, Liam Il-Young |
|
[JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 37.6] Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy |
SCIE | 1.7 | ONCOLOGY | YCHAE@nm.org; | ||
|
Chung, Min Sung (Chung, MS) |
Hanyang Univ, Coll Med, Dept Surg, Seoul 04763, South Korea |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) [JCR상위 5.6] Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers |
SCIE | 1.7 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
jasonksa@korea.ac.kr;khpark@korea.ac.kr; | ||
|
Cohen, Gordon (Cohen, G) |
AstraZeneca, Global Med Dev, Gaithersburg, MD USA |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Djunadi, Trie Arni (Djunadi, TA) |
Northwestern Univ, Feinberg Sch Med, Chicago, IL USA Richmond Univ, Med Ctr, Dept Internal Med, Staten Isl, NY USA |
|
|
[JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study [JCR상위 37.6] Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy |
SCIE | 1.7 | ONCOLOGY | YCHAE@nm.org; | ||
|
Du, Pan (Du, P) |
|
|
[JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. | SCIE | 1.7 | ONCOLOGY | ||||
|
Dwivedi, Ashish (Dwivedi, A) |
Indian Inst Toxicol Res, CSIR, Photobiol Lab, Syst Toxicol & Hlth Risk Assessment Grp, Vishvigyan Bhawan 31,Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India |
|
|
[JCR상위 1.7] Skin protection from solar ultraviolet radiation using natural compounds: a review | SCIE | 1.7 | CHEMISTRY, MULTIDISCIPLINARY;ENVIRONMENTAL SCIENCES;ENGINEERING, ENVIRONMENTAL | ankit.verma@mail.huji.ac.il;alessandra.zanoletti@unibs.it;2021321530@knu.ac.kr;adelodun.b@unilorin.edu.ng;kumarpankajgkv@gmail.com;foajibade@futa.edu.ng;lsilva8@cuc.edu.co;ankurphillips245@gmail.com;tkarthees@gmail.com;elza.bontempi@unibs.it;ashish.dwivedi1@iitr.res.in; | ||
|
Erinjeri, Joseph (Erinjeri, J) |
Mem Sloan Kettering Canc Ctr, Intervent Radiol Serv, New York, NY USA |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Escobar, Jose (Escobar, J) |
Hosp San Lucas Cardiol Sureste, Chiapas, Mexico Hosp San Lucas Cardiolog Sureste, Chiapas, Mexico |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Evans, Thomas (Evans, T) |
교신저자 | Vaccitech, Harwell, Oxon, South Korea |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | |
|
Gennaro, Nicolo (Gennaro, N) |
P-1776-2019 Gennaro, Nicolò |
|
[JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) |
SCIE | 1.7 | ONCOLOGY | ||||
|
Go, Junwon (Go, J) |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) | SCIE | 1.7 | ONCOLOGY | ||||
|
Gupta, Amit (Gupta, A) |
|
|
[JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) | SCIE | 1.7 | ONCOLOGY |
페이지 이동: